(Q39410894)

11 September 2017

Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: role of oxidative stress pathway genes (English)

1 reference

11 September 2017

0 references

1 reference

chronic schizophrenia

1 reference

B K Thelma

1

1 reference

11 September 2017

Arun K Tiwari

2

1 reference

11 September 2017

Smita N Deshpande

3

1 reference

11 September 2017

Bernard Lerer

4

1 reference

11 September 2017

Vishwajit L Nimgaonkar

5

1 reference

11 September 2017

language of work or name

English

0 references

publication date

21 February 2007

1 reference

11 September 2017

Schizophrenia Research

1 reference

11 September 2017

92

1 reference

11 September 2017

1-3

1 reference

11 September 2017

278-279

1 reference

Endothelial nitric oxide synthase in vascular disease: from marvel to menace

11 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2435191

Clinical implications of pharmacogenomics for tardive dyskinesia

11 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2435191

Oxidative mechanisms and tardive dyskinesia

11 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2435191

Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms

11 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2435191

A novel brain-targeted antioxidant (AD4) attenuates haloperidol-induced abnormal movement in rats: implications for tardive dyskinesia.

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2435191

II. Serotonin receptor gene polymorphisms and their association with tardive dyskinesia among schizophrenia patients from North India.

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2435191

NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2435191

Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group.

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2435191

Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: V. Association of CYP1A2 1545 C>T polymorphism

21 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17317105

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17317105

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17317105

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.SCHRES.2006.12.019

1 reference

11 September 2017

1 reference

11 September 2017

PubMed publication ID

17317105

1 reference